Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEX:MEDP 93 FCF Yield % is 4.21 as of Jul. 25, 2026, which is 19% below its 10-year median of 5.17. GuruFocus rates MEX:MEDP with a GF Score™ of 93/100 and a GF Value™ of MXN6,131.53. The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 77.1% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Medpace Holdings's FCF Yield % or its related term are showing as below:
MEX:MEDP'
s FCF Yield % Range Over the Past 10 Years
Min: 2.23 Med: 5.17 Max: 8.44
Current: 4.21
During the past 13 years, the highest FCF Yield % of Medpace Holdings was 8.44%. The lowest was 2.23%. And the median was 5.17%.
MEX:MEDP's FCF Yield % is ranked better than 77.1% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.355
vs MEX:MEDP: 4.21
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Medpace Holdings FCF Yield % Related Terms
Medpace Holdings FCF Yield % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MEDP vs ICLR, RVTY, CRL: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEX:MEDP) has a FCF Yield % of 4.21 as of Jul. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Medpace Holdings and its competitors. This is 19% below median its historical median of 5.17. Over the past decade, Medpace Holdings' FCF Yield % has ranged from 2.23 to 8.44. According to the industry distribution chart, Medpace Holdings ranks #49 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 22.9%.
Is Medpace Holdings' FCF Yield % too high?
Medpace Holdings' current FCF Yield % of 4.21 is 19% below median its 10-year median of 5.17. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 8.44. Based on the distribution chart, Medpace Holdings ranks #49 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' FCF Yield % compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #49 out of 214 companies for FCF Yield %. This places Medpace Holdings in the top 23% of its industry — outperforming the majority of peers. Historically, Medpace Holdings' own FCF Yield % has ranged from 2.23 to 8.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current FCF Yield % is 4.21, which is 19% below median its own 10-year median of 5.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current FCF Yield % of 4.21. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current FCF Yield % is 4.21, which is 19% below median its 10-year median of 5.17. Medpace Holdings' overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current FCF Yield % is 4.21 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
FCF Yield %: 4.21 (19% below median its 10-year median of 5.17)
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
93GF Score
Get the complete analysis for MEX:MEDP
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
